These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 35915886)
1. [Therapeutic options to reduce LDL-cholesterol beyond statins]. Weingärtner O; Marx N; Klose G; Laufs U Dtsch Med Wochenschr; 2022 Aug; 147(15):1001-1012. PubMed ID: 35915886 [TBL] [Abstract][Full Text] [Related]
2. [Modern lipid-lowering drugs-A means to counter the problem of undertreatment?]. Katzmann JL; Laufs U Inn Med (Heidelb); 2022 Dec; 63(12):1316-1322. PubMed ID: 35391570 [TBL] [Abstract][Full Text] [Related]
3. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N BMJ; 2022 May; 377():e069066. PubMed ID: 35508320 [TBL] [Abstract][Full Text] [Related]
4. Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab. Xu Q; Deng Y; Xiao J; Liu X; Zhou M; Ren Z; Peng J; Tang Y; Jiang Z; Tang Z; Liu L Curr Med Chem; 2021; 28(5):1025-1041. PubMed ID: 32368969 [TBL] [Abstract][Full Text] [Related]
5. Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias. Rached F; Santos RD Curr Cardiol Rep; 2021 Jun; 23(7):83. PubMed ID: 34081216 [TBL] [Abstract][Full Text] [Related]
6. Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease. Gu J; Sanchez RJ; Chauhan A; Fazio S; Rosenson RS J Clin Lipidol; 2022; 16(6):901-905. PubMed ID: 36319536 [TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein cholesterol lowering treatment: the current approach. Crismaru I; Pantea Stoian A; Bratu OG; Gaman MA; Stanescu AMA; Bacalbasa N; Diaconu CC Lipids Health Dis; 2020 May; 19(1):85. PubMed ID: 32375792 [TBL] [Abstract][Full Text] [Related]
8. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335 [TBL] [Abstract][Full Text] [Related]
9. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699 [TBL] [Abstract][Full Text] [Related]
10. Practical guide for the use of PCSK9 inhibitors in Portugal. Fontes-Carvalho R; Marques Silva P; Rodrigues E; Araújo F; Gavina C; Ferreira J; Morais J Rev Port Cardiol (Engl Ed); 2019 Jun; 38(6):391-405. PubMed ID: 31324407 [TBL] [Abstract][Full Text] [Related]
11. A Clinical Guide to Combination Lipid-Lowering Therapy. Russell C; Sheth S; Jacoby D Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190 [TBL] [Abstract][Full Text] [Related]
12. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. Lee S; Cannon CP Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475 [TBL] [Abstract][Full Text] [Related]
13. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. Chang Y; Eom S; Kim M; Song TJ Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109734 [TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering therapy: Guidelines to precision medicine. Su X; Cheng Y; Chang D Clin Chim Acta; 2021 Mar; 514():66-73. PubMed ID: 33359059 [TBL] [Abstract][Full Text] [Related]
15. [Up to date lipid lowering treatment]. Paragh G; Karádi I Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517 [TBL] [Abstract][Full Text] [Related]
16. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965 [TBL] [Abstract][Full Text] [Related]
17. [A decade of progress in the management of dyslipidemia]. Wallemacq C; Paquot N Rev Med Liege; 2020 May; 75(5-6):386-391. PubMed ID: 32496685 [TBL] [Abstract][Full Text] [Related]
18. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances. Atar D; Langslet G; Tonstad S Kardiol Pol; 2022; 80(7-8):741-749. PubMed ID: 35521719 [TBL] [Abstract][Full Text] [Related]